Second-Line Docetaxel Affirmed for Esophagogastric CancerSecond-Line Docetaxel Affirmed for Esophagogastric Cancer

Second-line docetaxel therapy improved survival and pain symptoms, and was not associated with any deterioration in quality of life. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news